Brcaone 150mg Supplier Abu Dhabi | Bulk Pharmaceutical Exporter India

Brcaone 150mg Tablet: Targeted PARP Inhibition for BRCA-Mutated Malignancies

Are you searching for a reliable Brcaone 150 mg tablet exporter from India? Ernest Oncology, a specialized division of Ernest Pharmaceutical Pvt. Ltd., is a premier global supplier and bulk distributor of advanced targeted therapies. We serve critical healthcare markets in the UK (London), USA, UAE (Abu Dhabi), Australia, and South Africa, facilitating the international supply of high-potency oncology medications through an expert B2B pharmaceutical network.

Detailed Product Overview: What is Brcaone 150mg?

Brcaone 150mg is a potent oral medication containing the active ingredient Olaparib. It belongs to a sophisticated class of antineoplastic agents known as PARP (Poly ADP-ribose Polymerase) Inhibitors.

Brcaone is specifically engineered for patients whose tumors have a defect in the BRCA1 or BRCA2 genes. By exploiting these genetic vulnerabilities, Brcaone offers a highly targeted approach to treating specific types of ovarian, breast, pancreatic, and prostate cancers, providing a lifeline for patients with advanced or recurrent disease.

Primary Therapeutic Indications;

Brcaone 150 mg is clinically indicated for:

• Ovarian Cancer: Maintenance treatment for adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy.

• Breast Cancer: For patients with HER2-negative, germline BRCA-mutated (gBRCAm) metastatic breast cancer who have been previously treated with chemotherapy.

• Pancreatic Cancer: Maintenance treatment of adult patients with gBRCAm metastatic pancreatic adenocarcinoma.

• Prostate Cancer: For patients with metastatic castration-resistant prostate cancer (mCRPC) and specific gene mutations.

Mechanism of Action: How Brcaone 150 mg Works: 

Brcaone works through a biological concept known as "Synthetic Lethality."

1. Inhibition of PARP Enzymes: PARP enzymes are responsible for repairing single-strand breaks in DNA. Brcaone binds to and inhibits these enzymes.

2. DNA Damage Accumulation: When PARP is blocked, single-strand breaks evolve into double-strand breaks during cell replication.

3. Selective Cancer Cell Death: In normal cells, these double-strand breaks are repaired by a process called Homologous Recombination (which requires functional BRCA proteins). In BRCA-mutated cancer cells, this repair mechanism is broken. The accumulation of irreparable DNA damage forces the cancer cell to undergo apoptosis (cell death).

Administration and Dosage:

• Route: Oral administration (tablets).

• Dosage: The standard recommended dose is typically 300 mg (two 150 mg tablets) taken twice daily for a total daily dose of 600 mg.

• Flexibility: Brcaone can be taken with or without food. Tablets must be swallowed whole and not chewed, crushed, or dissolved.

Safety Profile & Side Effects:

Healthcare providers should monitor patients for common and serious adverse reactions:

• Hematological Toxicity: Including anemia, neutropenia, and leukopenia. Complete blood counts (CBC) are required monthly.

• Gastrointestinal Issues: Nausea, vomiting, diarrhea, and stomatitis.

• MDS/AML: Rare but serious risks of Myelodysplastic Syndrome or Acute Myeloid Leukemia.

• Common Symptoms: Fatigue, dizziness, and headache.

Why source Brcaone 150 mg from Ernest Oncology?

• Global Export Mastery: We handle complex regulatory requirements for pharmaceutical exports to USA, UK, UAE, Australia, and South Africa. 

• Authenticity Guaranteed: Direct procurement from GMP-certified facilities, ensuring 100% product integrity for every exporter from India shipment.

• Bulk Supply Stability: We maintain a consistent inventory of 150mg tablets to ensure that international hospitals and pharmacies avoid treatment gaps.

• B2B Logistics Excellence: Professional packaging and track-and-trace capabilities for secure international transit.